HABS-HD - Core D - Omics Core

HABS-HD OMICS核心(核心D)-摘要 生物体液，包括血液和脑脊液，单独或联合使用，可能为阿尔茨海默氏症提供敏感的生物标记物 疾病(AD)的诊断、预后和治疗。然而，到目前为止，还没有大规模的系统性多层次 “组学”研究结合AT(N)定义(淀粉样蛋白[A]、tau[T]、神经变性)进行 [n])非裔美国人、墨西哥裔美国人和非西班牙裔白人中的生物标志物。我们的数据显示 (1)基于组学的生物标记物在不同的人群中有所不同，包括血浆AT(N)生物标记物，(2) 基于组学的生物标记物可以高度准确地检测临床诊断的轻度认知障碍 (3)不同种族/民族之间的情况有所不同。最近， 我们的数据表明，蛋白质组图谱在检测神经退行性变方面是准确的，但同样的，图谱 不同种族/民族之间的差异。鉴于记录在案的AT(N)生物标记物按种族/民族的差异 ，多水平的组学研究很可能会突出新的人群特有的途径 认知功能减退、MCI和AD。此外，随着FDA最近批准了一种治疗疾病的淀粉样药物， 来自OMICS核心(核心D)的数据比以往任何时候都更加重要，可以迅速适当地为小说提供信息 量身定做的临床试验。核心D将监督收集、处理、化验、储存和分发 为所有项目提供关键数据的样本(核心-项目交互)、核心(核心-核心交互)、 以及全球调查人员(跨队列互动)。目标1：生成高质量的基因组数据。目标2： 生成高质量的蛋白质组数据。目标3：生成高质量的Exosome数据。目标4：产生快感 高质量的新陈代谢数据。目标5：为项目(核心-核心、核心-项目)提供关键组学数据 交互)。目标6：向外部调查人员提供数据和专门知识。

HABS-HD OMICS CORE (CORE D) - ABSTRACT Biofluids, including blood and CSF, alone or in combination, may provide sensitive biomarkers for Alzheimer’s disease (AD) diagnosis, prognosis, and theragnosis. To date, however, no large-scale systematic multi-level “omics” study has been conducted in combination with AT(N) defined (amyloid [A], tau [T], neurodegeneration [N]) biomarkers among African Americans, Mexican Americans, and non-Hispanic whites. Our data suggests that (1) omics-based biomarkers vary across diverse populations, including plasma AT(N) biomarkers, (2) omics-based biomarkers can be highly accurate in detecting clinically diagnosed mild cognitive impairment (MCI) and dementia across populations, but (3) the profiles differ between racial/ethnic groups. More recently, our data suggests that a proteomic profile is accurate in detecting neurodegeneration, but again the profiles vary between racial/ethnic groups. Given the documented differences in AT(N) biomarkers by racial/ethnic groups, it is likely that multi-level omics investigations will highlight novel population-specific pathways for cognitive decline, MCI and AD. Additionally, with the recent FDA approval of a disease modifying amyloid drug, the data from the Omics Core (Core D) is more important than ever and can rapidly inform novel, appropriately tailored, clinical trials. Core D will oversee the collection, processing, assays, storage and distribution of samples to provide critical data to all Projects (Core – Project Interactions), Cores (Core-Core interactions), and to global investigators (Cross-Cohort Interactions). Aim 1: Generate high quality genomic data. Aim 2: Generate high quality proteomic data. Aim 3: Generate high quality exosome data. Aim 4: Generate high quality metabolomic data. Aim 5: Provide critical omics data for projects (Core-Core, Core-Project Interactions). Aim 6: Provide data and expertise to external investigators.